Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of APN1125 in healthy subjects
NCT02331433Phase 1Completed
- Sponsor
- CoMentis, Inc.
- Start
- Dec 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in schizophrenia comparing APN1125 with Placebo Comparator (2 arms). Primary endpoints: Assessment of safety and tolerability via adverse events at 8 days, Assessment of safety and tolerability via vital signs at 8 days and 3 more. Started Dec 2014; status: completed.
02
Drugs
APN1125
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02331433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02331433.